Risks Associated with Vortioxetine in the Established Therapeutic Indication

Title:Risks Associated with Vortioxetine in the Established Therapeutic Indication

Volume: 19 Issue: 5

Author(s): Akansha Verma and Anoop Kumar*

Affiliation:

• Department of Pharmacology and Toxicology, National Institute of Pharmaceutical, Education and Research (NIPER), Raeberali, Lucknow (U.P.)- 226002,India

Keywords: Adverse drug reactions, vortioxetine, major depressive disorder (MDD), marketing authorization holder (MAH), regulatory authorities (RAs), summary of product characteristics (SmPC).

Abstract:

Background: Vortioxetine is approved for the treatment of Major Depressive Disorder (MDD). However, the safety of this drug in a large group of populations is still unclear. Thus, we have tried to analyze the risk profile of vortioxetine.

Material and Methods: The data related to the risk profile of vortioxetine has been extracted from Pub-Med from January 2014 to May 2019. The adverse drug reactions (ADRs) have been categorized into listed and unlisted categories as per the Summary of product characteristics (SmPC) of the innovator. Further, unlisted ADRs have been analyzed as per Naranjo Scale.

Results: Galactorrhea, hyperprolactinemia, glycolimia, exacerbation of anxiety, weight gain, edema, excessive itching, petechiae, and ecchymoses have been observed with the use of vortioxetine and falls under the unlisted category. Further, the causality assessment results have shown a probable relation between vortioxetine and galactorrhea, hyperprolactinemia, edema, excessive itching, ecchymoses, and petechiae. Weight gain, glycolimia and exacerbation of anxiety have a possible relationship with vortioxetine. The common ADRs observed with the use of vortioxetine are nausea, diarrhea, constipation, vomiting, pruritus, including pruritus generalized, abnormal dreams, and dizziness.

Conclusion: In conclusion, more data is required to establish a strong relationship between vortioxetine and reported unlisted ADRs.

Cite this article as:

Verma Akansha and Kumar Anoop *, Risks Associated with Vortioxetine in the Established Therapeutic Indication, Current Neuropharmacology 2021; 19 (5) . https://dx.doi.org/10.2174/1570159X18666200818195720